Accomplishments

Dr. Balaji Ramachandran

Dr. Balaji was involved in the generation and validation of preclinical mouse models for anticancer drug development. He has several years of expertise in non-invasive molecular imaging technology with a core interest in "in *vivo* imaging of new cancer therapeutics". His other interests are into in vivo pharmacology and drug repurposing. Currently, he has received a SERB grant which attempts to model EWS-FLI1 driven Ewing sarcoma reporter mice.

Key publications:

1. Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma. **Ramachandran B***, Rajkumar T and Gopisetty G. Am. J.Translational Res. 2021 Nov 15;13(11):12181-12194.

2. SERMs suppresses the growth of ER α positive cervical cancer xenografts through predominant inhibition of extra-nuclear ER α expression. **Ramachandran B***, Murhekar k and Sundersingh S. Am. J.Cancer Res. 2021 Jun 15;11(6):3335-3353.

3. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft. Natarajan A, Ramachandran B, Gopisetty G, Jayavelu S, Sundersingh S, Rajkumar T. Naunyn Schmiedebergs Arch Pharmacol. 2021 Feb;394(2):361-371. IF: 3.00

4. Functional association of oestrogen receptors with HPV infection in Cervical Carcinogenesis. **Ramachandran B.*** Endocrine-Related Cancer. 2017 April 24, R99–R108. IF: 5.6. Selected for Journal Based Learning & top downloaded article.

5. Molecular imaging of NF-Y transcriptional activity maps proliferation sites in live mice; Goeman.F`, Manni.I`, Artuso.S`, Ramachandran.B, Toietta.G, Bossi.G, Rando.G, Cencioni.C, Germoni.S, Straino.S, Capogrossi.M, Bacchetti.S, Maggi.A, Sacchi.A, Ciana.P, Piaggio.G. Mol Biol Cell – Cover page article. 2012 Apr;23(8):1467-74. (`first authors).

*Corresponding author

Google scholar link: <u>https://scholar.google.com/citations?user=Ux3eLt0AAAAJ&hl=en</u>